Prophylactic colchicine therapy after ablation in AF fails to reduce incident pericarditis
A study published in JACC: Clinical Electrophysiology entitled "Prophylactic Colchicine After Radiofrequency Ablation of Atrial Fibrillation: The PAPERS Study" by a team of researchers has suggested that there is no benefit associated with postprocedural prophylactic colchicine therapy following atrial fibrillation or AF ablation. This study randomized 139 patients to either standard of care...
A study published in JACC: Clinical Electrophysiology entitled "Prophylactic Colchicine After Radiofrequency Ablation of Atrial Fibrillation: The PAPERS Study" by a team of researchers has suggested that there is no benefit associated with postprocedural prophylactic colchicine therapy following atrial fibrillation or AF ablation. This study randomized 139 patients to either standard of care or colchicine treatment after radiofrequency ablation for AF to investigate the risks and benefits associated with the prophylactic use of colchicine to prevent Pericarditis (post-AF ablation). They found no significant difference in the incidence of post-ablation pericarditis between the treatment groups (10.6% vs 9.6%). They reported a higher rate of gastrointestinal discomfort in the colchicine group.
They concluded that Prophylactic colchicine therapy initiated after the ablation procedure in AF patients did not affect the incidence of post-ablation Pericarditis and is tied to an increased incidence of GI side effects.
It is already known that Pericarditis is common after radiofrequency ablation for atrial fibrillation. There needs to be more data on prevention strategies and, thus, significant heterogeneity in practice regarding colchicine use.
In this study, Study investigators hypothesized that an empirical post-AF ablation treatment protocol with colchicine may reduce pericarditis incidence and severity.
PAPERS (Post-Ablation PEricarditis Reduction Study) quantified the risks and benefits of prophylactic use of colchicine to prevent Pericarditis following AF ablation. They measured the primary endpoint as clinical pericarditis development within two weeks after ablation.
The critical points of this study are:
· There were two groups: A, the standard of care arm and B, the study arm.
· 66 Patients in group A received no postprocedure prophylaxis.
· 73 Patients in group B received colchicine 0.6 mg orally twice daily for seven days starting immediately after postprocedure (group B; study arm).
· All participants underwent a follow-up survey at 14 days postoperatively.
· The clinical Pericarditis in groups A and B was 7/66 and 7/73, constituting 10.6 % and 9.6%, respectively.
· The rate of gastrointestinal discomfort in groups A and B was 10/66 and 34/73, constituting 15 % and 47 %, respectively.
· Those who underwent cavotricuspid isthmus ablation had greater Pericarditis incidence in addition to pulmonary vein isolation (34 % and 8.7%, respectively).
They said that Prophylactic colchicine therapy initiated following the ablation procedure in AF patients did not affect post-ablation pericarditis incidence. They noted its association with an increased incidence of GI side effects.
Further reading:
https://www.sciencedirect.com/science/article/abs/pii/S2405500X23000920?via%3Dihub
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd